Meeder Advisory Services Inc. Has $1.53 Million Stake in Zoetis Inc. (NYSE:ZTS)

Meeder Advisory Services Inc. lowered its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,407 shares of the company’s stock after selling 169 shares during the period. Meeder Advisory Services Inc.’s holdings in Zoetis were worth $1,533,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Callahan Advisors LLC increased its stake in Zoetis by 90.4% in the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after acquiring an additional 6,221 shares during the period. CIBC Asset Management Inc grew its stake in shares of Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after purchasing an additional 46,050 shares during the period. Pensionfund Sabic raised its holdings in shares of Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock worth $1,825,000 after buying an additional 4,000 shares in the last quarter. PFW Advisors LLC bought a new position in shares of Zoetis during the 4th quarter worth approximately $1,764,000. Finally, Alberta Investment Management Corp boosted its stake in Zoetis by 2,050.0% in the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock valued at $4,904,000 after buying an additional 28,700 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at $1,868,244.30. This represents a 9.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,862 shares of company stock worth $312,254 over the last ninety days. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of analyst reports. Stifel Nicolaus cut their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Barclays lifted their price target on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Piper Sandler upped their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Morgan Stanley cut their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. Finally, StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $215.90.

Zoetis Stock Up 1.0 %

NYSE:ZTS opened at $163.59 on Thursday. The company has a market cap of $73.25 billion, a price-to-earnings ratio of 29.91, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The stock’s fifty day moving average price is $166.20 and its two-hundred day moving average price is $173.98. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.22%. The ex-dividend date is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.